Ligand development using PDE4B crystal structures

• US 20050079548A1
• Filed: 07/07/2004
• Published: 04/14/2005
• Est. Priority Date: 07/07/2003
• Status: Abandoned Application

• Current Assignee: Plexxikon Inc (Daiichi Sankyo Company Limited)
• Original Assignee: Plexxikon Inc (Daiichi Sankyo Company Limited)
• Inventors: Artis, Dean R., Bollag, Gideon, Milburn, Michael V., Martin, Fernando, Card, Graeme, Zhang, Kam
• Application Number:
  US10/886,949
• Publication Number:
  US 20050079548A1
• Time in Patent Office: Days
• US Class Current: 435/7.100
• CPC Class Codes: G16C 20/50 Molecular design, e.g. of drugs

Abstract

The use of PDE4B crystals and strucural information for identifying molecular scaffolds and for developing ligands that bind to and modulate PDE4B is described.

Claims

1. A method for developing ligands binding to PDE4B, comprising

identifying as molecular scaffolds one or more compounds that bind to a binding site of PDE4B;

determining the orientation of at least one molecular scaffold in co-crystals with PDE4B; and

identifying chemical structures of said molecular scaffolds, that, when modified, alter the binding affinity or binding specificity or both between the molecular scaffold and PDE4B; and

synthesizing a ligand wherein one or more of the chemical structures of the molecular scaffold is modified to provide a ligand that binds to PDE4B with altered binding affinity or binding specificity or both.

2. The method of claim 1, wherein said molecular scaffold is a weak binding compound.

3. The method of claim 1, wherein said molecular scaffold binds to a plurality of phosphodiesterases.

4. The method of claim 1, wherein said molecular scaffold includes the structure of Scaffold core I.

5. The method of claim 1, wherein said molecular scaffold includes the structure of Scaffold core II.

6. The method of claim 1, wherein said molecular scaffold includes the structure of Scaffold core III.

7. A method for developing ligands specific for PDE4B, comprising

identifying a compound that binds to a plurality of phosphodiesterases;

and

determining whether a derivative of said compound has greater specificity for PDE4B than said compound.

8. The method of claim 7, wherein said compound binds to PDE4B with an affinity at least 10-fold greater than for binding to any of said plurality of phosphodiesterases.

9. The method of claim 8, wherein said compound interacts with at least one conserved PDE4B active site residue.

10. The method of claim 7, wherein said compound binds weakly to said plurality of phosphodiesterases.

11. The method of claim 7, wherein said plurality of phosphodiesterases comprises PDE5A.

12. The method of claim 7, wherein said plurality of phosphodiesterases comprises PDE4D.

13. The method of claim 7, wherein said compound includes Scaffold core I.

14. The method of claim 7, wherein said compound includes Scaffold core II.

15. The method of claim 7, wherein said compound includes Scaffold core III.

16. A co-crystal of PDE4B and a PDE4B binding compound, wherein said binding compound includes a structural core selected from the group consisting of Scaffold core I, Scaffold core II, and Scaffold core III.

17. The co-crystal of claim 16, wherein said co-crystal is in an X-ray beam.

18. A crystalline form of PDE4B phosphodiesterase domain, having coordinates as described in Table 1.

19. A method for obtaining a crystal of PDE4B, comprising subjecting PDE4B protein at 5-20 mg/ml to crystallization condition substantially equivalent to 30% PEG 400, 0.2M MgCl₂, 0.1M Tris pH 8.5, 1 mM binding compound, at 4°

C.;

or 20% PEG 3000, 0.2M Ca(OAc)₂, 0.1M Tris pH 7.0, 1 mM binding compound, 15.9 mg/ml protein at 4°

C.;

or 1.8M-2.0M ammonium sulphate, 0.1 M CAPS pH 10.0-10.5, 0.2M Lithium sulphate.

20. The method of claim 19, further comprising optimizing said crystallization condition.

21. An electronic representation of a crystal structure of PDE4B, containing atomic coordinate representations corresponding to the coordinates listed in Table 1.

22. The electronic representation of claim 21, comprising a schematic representation.

23. The electronic representation of claim 21, wherein said PDE4B consists essentially of a PDE4B phosphodiesterase domain.

24. The electronic representation of claim 21, further comprising atomic coordinate representations corresponding to a PDE4B binding compound.

25. A method for developing a biological agent, comprising

analyzing a PDE4B crystal structure and identifying at least one sub-structure for forming a said biological agent.

26. The method of claim 25, wherein said substructure comprises an epitope, and said method further comprises developing antibodies against said epitope.

27. The method of claim 25, wherein said sub-structure comprises a mutation site expected to provide altered activity, and said method further comprises creating a mutation at said site thereby providing a modified PDE4B.

28. The method of claim 25, wherein said sub-structure comprises an attachment point for attaching a separate moiety.

29. The method of claim 25, wherein said separate moiety is selected from the group consisting of a peptide, a polypeptide, a solid phase material, a linker, and a label.

30. The method of claim 25, further comprising attaching said separate moiety.

31. A method for attaching a PDE4B binding compound to an attachment component, comprising

identifying energetically allowed sites for attachment of a said attachment component on a phosphodiesterase binding compound;

and

attaching said compound or derivative thereof to said attachment component at said energetically allowed site.

32. The method of claim 31, wherein said attachment component is a linker for attachment to a solid phase medium, and said method further comprises attaching said compound or derivative to a solid phase medium through a linker attached at a said energetically allowed site.

33. The method of claim 32, wherein said linker is a traceless linker.

34. The method of claim 32, wherein said phosphodiesterase binding compound or derivative thereof is synthesized on a said linker attached to said solid phase medium.

35. The method of claim 34, wherein a plurality of said compounds or derivatives are synthesized in combinatorial synthesis.

36. The method of claim 32, wherein attachment of said compound to said solid phase medium provides an affinity medium.

37. The method of claim 31, wherein said attachment component comprises a label.

38. The method of claim 37, wherein said label comprises a fluorophore.

39. A modified compound, comprising

a PDE4B binding compound, with a linker moiety attached thereto at an energetically allowed site for binding of said modified compound to PDE4B.

40. The compound of claim 39, wherein said linker is attached to a solid phase.

41. The compound of claim 39, wherein said linker comprises or is attached to a label.

42. The compound of claim 39, wherein said linker is a traceless linker.

43. A method for identifying a compound having selectivity between PDE4B and PDE4D, comprising

analyzing whether a compound differentially interacts in PDE4B and PDE4D in at least one of PDE4B/4D selectivity sites 1, 2, and 3, wherein a differential interaction is indicative of said selectivity.

44. The method of claim 43, wherein said analyzing comprises fitting an electronic representation of said compound in electronic representations of binding sites of PDE4B and PDE4D, and determining whether said compound differentially interacts based on said fitting.

45. The method of claim 43, comprising

selecting an initial compound that binds to both PDE4B and PDE4D;

fitting an electronic representation of said initial compound in electronic representations of binding sites of PDE4B and PDE4D;

modifying said electronic representation of said initial compound with at least one moiety that interacts with at least of PDE4B/4D selectivity sites 1, 2, and 3; and

determining whether the modified compound differentially binds to PDE4B and PDE4D.

46. The method of claim 45, wherein said modified compound binds differentially to a greater extent than does said initial compound.

47. The method of claim 43, further comprising assaying a compound that differentially interacts for differential activity on PDE4B and PDE4D.

48. A method for treating a subject for a PDE4B related disease or condition, comprising

administering to said subject a compound comprising a structural core selected from the group consisting of Scaffold core I, Scaffold core II, and Scaffold core III.

49. The method of claim 48, wherein said compound comprises the sildenafil core.

50. The method of claim 48, wherein said compound comprises the vardenafil core.